SCHEMBL246490

SCHEMBL246490

O=[C]c1ccccc1/[C]=N/S(=O)(=O)O

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837075 0.74
SCHEMBL8384 0.72 TSHR (0.35) TSHRSMN1; SMN2
SCHEMBL11901033 0.72 F2 (0.30)
SCHEMBL998537 0.68 MYC (0.41) TSHRSMN1; SMN2
SCHEMBL11489811 0.67 MIF (0.43) TSHR
SCHEMBL306253 0.66 TSHR (0.37) TSHRSMN1; SMN2
SCHEMBL11787881 0.64 SLC16A3 (0.38) TSHRSMN1; SMN2
SCHEMBL98562 0.61 TSHR (0.50) TSHRSMN1; SMN2
SCHEMBL3940375 0.61
SCHEMBL10582118 0.61 HDAC8 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3486248-B1 IMPROVED METHODS FOR THE ACYLATION OF MAYTANSINOL IMMUNOGEN INC (US) 2021-04-07 EP claimed
EP-3486248-A1 IMPROVED METHODS FOR THE ACYLATION OF MAYTANSINOL ImmunoGen, Inc. (US) 2019-05-22 EP claimed
EP-2900676-B1 IMPROVED METHOD FOR THE ACYLATION OF MAYTANSINOL IMMUNOGEN INC (US) 2018-12-19 EP claimed
US-9796731-B2 Methods for the acylation of maytansinol IMMUNOGEN, INC. (US) 2017-10-24 US claimed
US-20170137440-A1 METHODS FOR THE ACYLATION OF MAYTANSINOL IMMUNOGEN SWITZERLAND GMBH (CH) 2017-05-18 US claimed
EP-1390370-B1 METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS IMMUNOGEN INC (US) 2016-04-13 EP claimed
EP-2348024-B1 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents IMMUNOGEN INC (US) 2015-07-29 EP claimed
US-8618042-B2 Binding molecules and methods of use thereof BIOGEN IDEC MA INC. (US) 2013-12-31 US claimed
EP-1463558-B1 CYTOTOXIC AGENTS BEARING A REACTIVE POLYETHYLENE GLYCOL MOIETY, CYTOTOXIC CONJUGATES COMPRISING POLYETHYLENE GLYCOL LINKING GROUPS, AND METHODS OF MAKING AND USING THE SAME IMMUNOGEN INC (US) 2012-06-06 EP claimed
EP-2348024-A2 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents ImmunoGen, Inc. (US) 2011-07-27 EP claimed
EP-1390370-A4 METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS IMMUNOGEN INC (US) 2005-07-06 EP claimed
JP-2005517032-A 2005-06-09 JP claimed
EP-1463558-A2 CYTOTOXIC AGENTS BEARING A REACTIVE POLYETHYLENE GLYCOL MOIETY, CYTOTOXIC CONJUGATES COMPRISING POLYETHYLENE GLYCOL LINKING GROUPS, AND METHODS OF MAKING AND USING THE SAME Immunogen, Inc. (US) 2004-10-06 EP claimed
US-6716821-B2 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same IMMUNOGEN INC. 2004-04-06 US claimed
EP-1390370-A1 METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS Immunogen, Inc. (US) 2004-02-25 EP claimed
US-20040001838-A1 CYTOTOXIC AGENTS BEARING A REACTIVE POLYETHYLENE GLYCOL MOIETY, CYTOTOXIC CONJUGATES COMPRISING POLYETHYLENE GLYCOL LINKING GROUPS, AND METHODS OF MAKING AND USING THE SAME IMMUNOGEN, INC. 2004-01-01 US claimed
WO-2003068144-A2 CYTOTOXIC AGENTS IMMUNOGEN, INC. (US) 2003-08-21 WO claimed
US-20030055226-A1 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents IMMUNOGEN, INC. 2003-03-20 US claimed
WO-2002098883-A1 METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS IMMUNOGEN, INC. (US) 2002-12-12 WO claimed
US-6441163-B1 COUPLING MAYTANSINOIDS HAVING DISULFIDE LINKER BEARING REACTIVE MOIETY TO SUCH AS ANTIBODIES WITHOUT PRIOR MODIFICATION OF SAID ANTIBODY; ONE-STEP, HIGH YIELD, LOWER COST IMMUNOGEN, INC. 2002-08-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055226-A1 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents SPR, SELPLG, CD2BP2 TSHR 2205/4885SMN1; SMN2 1810/4885
US-20170137440-A1 METHODS FOR THE ACYLATION OF MAYTANSINOL NAAA, NPPA, AANAT TSHR 3484/4885SMN1; SMN2 1907/4885
US-20040001838-A1 CYTOTOXIC AGENTS BEARING A REACTIVE POLYETHYLENE GLYCOL MOIETY, CYTOTOXIC CONJUGATES COMPRISING POLYETHYLENE GLYCOL LINKING GROUPS, AND METHODS OF MAKING AND USING THE SAME MCL1, CD47, BAX TSHR 2602/4885SMN1; SMN2 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.